Skip to Main Content

Author Details

Andries M Bergman
The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital
1994
136
36
PMIDPaper TitleJournal TitlePublished Year
36224377Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.Prostate Cancer Prostatic Dis2023
37554550Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.Cancer Res Commun2023
37370685Radiogenomics Analysis Linking Multiparametric MRI and Transcriptomics in Prostate Cancer.Cancers (Basel)2023
37271632Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.Eur Urol2023
37333335A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.bioRxiv2023
37296924Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options.Cancers (Basel)2023
36654783Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl).Eur Urol Open Sci2023
36874601Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.Eur Urol Open Sci2023
36460134Serum testosterone measured by liquid chromatography-tandem mass spectrometry is an independent predictor of response to castration in metastatic hormone-sensitive prostate cancer.Clin Chim Acta2023
36865297Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients.medRxiv2023
36372736Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review.Eur Urol Oncol2023
36379811Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer.Urol Oncol2023
34446849Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.Prostate Cancer Prostatic Dis2022
35509021Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.Clin Epigenetics2022
35467095Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.Cancer Chemother Pharmacol2022
35754340Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.Cancer Discov2022
36450752Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.Nat Commun2022
36107324Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.Adv Exp Med Biol2022
36302495Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.Int J Radiat Oncol Biol Phys2022
36125208Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.Endocrinology2022
35918785Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays.Clin Chem Lab Med2022
35016887A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer.Clin Genitourin Cancer2022
35314962Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer.Drugs Real World Outcomes2022
34848157Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands.Clin Genitourin Cancer2022
31601523Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.Eur Urol Oncol2021
33744986Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.Cancer Chemother Pharmacol2021
33576154Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.Mol Oncol2021
33709626ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.Cancer Rep (Hoboken)2021
33746212The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.Prostate Cancer Prostatic Dis2021
34737261Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.Nat Commun2021
34736509Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial.Trials2021
34489572An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.Nat Cell Biol2021
34415798High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry.J Palliat Med2021
34503156Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation.Cancers (Basel)2021
34131070The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics.Mol Cancer Res2021
34217697Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications.Clin Chim Acta2021
34211036A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.Sci Rep2021
33975627Functional mapping of androgen receptor enhancer activity.Genome Biol2021
33431146Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.Value Health2021
33356545The intravenous to oral switch of taxanes: strategies and current clinical developments.Future Oncol2021
32362484Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.Eur Urol Focus2021
32172196Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme.Eur J Cancer2020
31875956A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.Int J Cancer2020
31804970Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program.Endocr Relat Cancer2020
31767448Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.Clin Genitourin Cancer2020
33112397Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.JAMA Netw Open2020
32690948Prostate cancer reactivates developmental epigenomic programs during metastatic progression.Nat Genet2020
32908142Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.Nat Commun2020
32928177Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.BMC Cancer2020
32727269Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.Nucleosides Nucleotides Nucleic Acids2020
  • 1 - 50 of 136

Recommended Authors

Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 8
Zafeiris Zafeiriou
Theageneion Anticancer Hospital
Career Start Year 2013
Number of shared co-authors 17
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 16
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 9
Roberta Ferraldeschi
Astex Pharmaceuticals
Career Start Year 2004
Number of shared co-authors 17
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Career Start Year 2003
Number of shared co-authors 27
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 26
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2000
Number of shared co-authors 27
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 24
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 21
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Career Start Year 1997
Number of shared co-authors 30
Primo N Lara
University of California Davis Comprehensive Cancer Center
Career Start Year 1996
Number of shared co-authors 24
Phuoc T Tran
University of Maryland School of Medicine
Career Start Year 1996
Number of shared co-authors 18
Michael A Carducci
Johns Hopkins School of Medicine
Career Start Year 1995
Number of shared co-authors 23
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 13
Lance C Pagliaro
Mayo Clinic
Career Start Year 1993
Number of shared co-authors 7
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 16
Edwin M Posadas
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 26
Urban Emmenegger
Odette Cancer Centre
Career Start Year 1991
Number of shared co-authors 10
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 2
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 28
Eric J Small
University of California san francisco
Career Start Year 1985
Number of shared co-authors 32
David C Smith
Rogel Comprehensive Cancer Center, University of Michigan ann arbor
Career Start Year 1985
Number of shared co-authors 19
Maha Hussain
Northwestern University
Career Start Year 1984
Number of shared co-authors 27
Helen J Ross
Mayo Clinic
Career Start Year 1982
Number of shared co-authors 11
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1981
Number of shared co-authors 29
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 34
Mario A Eisenberger
Johns Hopkins University
Career Start Year 1977
Number of shared co-authors 22
James H Doroshow
National Cancer Institute, National Institutes of Health
Career Start Year 1974
Number of shared co-authors 3
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 1

Collaborators

Wilbert Zwart
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 38
Inge M van Oort
Radboud University Medical Center
Co-authored papers 18
Niven Mehra
Radboud university medical center
Co-authored papers 13
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Co-authored papers 13
Tesa M Severson
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 9
Paul Hamberg
Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam
Co-authored papers 9
Ronald de Wit
Erasmus MC Cancer Institute
Co-authored papers 8
Michiel S van der Heijden
the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
Co-authored papers 8
Matthew L Freedman
Dana-Farber Cancer Institute
Co-authored papers 6
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 6
Katja K H Aben
Co-authored papers 6
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 5
Yanyun Zhu
Jiangsu Collaborative Innovation Center for Solid Organic Waste Resource Utilization
Co-authored papers 5
Geert J L H van Leenders
Erasmus MC Cancer Institute, University Medical Center
Co-authored papers 4
Mark M Pomerantz
Dana-Farber Cancer Institute
Co-authored papers 4
Guido Jenster
Erasmus University Medical Center
Co-authored papers 4
Martin E Gleave
University of British Columbia
Co-authored papers 4
Jan H M Schellens
Department of Pharmaceutical Sciences, Utrecht University
Co-authored papers 3
Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 3
Sylvan C Baca
Co-authored papers 3
Eva Corey
University of Washington School of Medicine
Co-authored papers 3
Bogdan Pasaniuc
David Geffen School of Medicine, University of California los angeles
Co-authored papers 3
Bauke Ylstra
Cancer Center Amsterdam, Vrije Universiteit Amsterdam
Co-authored papers 3
Amina Zoubeidi
University of British Columbia
Co-authored papers 3
Kim N Chi
University of British Columbia
Co-authored papers 3
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Emile E Voest
The Netherlands Cancer Institute
Co-authored papers 3
Takafumi N Yamaguchi
University of California los angeles
Co-authored papers 2
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 2
Arnulf Stenzl
Eberhard Karls University of Tubingen
Co-authored papers 2
Release 1.2